T Cell Killing Assay

T Cell Killing Assay


Aquila has established specialised immuno-oncology in vitro protocols to assess the ability of antibodies/compounds to modulate the effector function of immune cell subsets and initiate a killing response (apoptosis) towards cultured tumour cells. It is designed as a T cell (or NK cell) killing assay. This can be established either as a cytotoxic T cell assay or an antibody dependant cell-mediated cytotoxicity (ADCC) assay (NK cells).

Target tumour cells are labelled with NucLightTM Red (for tumour cell counting) and seeded into a 96-well plate, and treated with caspase 3/7 along with compounds under investigation. Immune cells are added (either as PBMC, CD8+ or NK cells, depending on target of choice) and the plate is incubated in the IncuCyte ZOOM® for a defined period of time. This technology allows real-time visualisation and automated analysis of immune cell-mediated killing of tumour cells.

Assay Read-Outs:

  • Measurement of apoptosis
  • Proliferation of tumour cells
  • Supernatant and cellular cytokine expression e.g. IFN-γ by flow cytometry, ELISA or multiplex

Contact us to discuss your T cell killing assay study requirements.


We’d be happy to discuss any service or product you may be interested in.

Aquila BioMedical Ltd.
Nine, Edinburgh BioQuarter
9, Little France Road
EH16 4UX

Tel: +44 (0) 131 658 5164
Email: info@aquila-bm.com